We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Realm Thera. | LSE:RLM | London | Ordinary Share | GB00B3XBCR18 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 10.00 | 13.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMRLM
RNS Number : 3760A
Realm Therapeutics PLC
23 March 2017
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Annual Report and Accounts Available
23 March 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, confirms that, further to the announcement of its Final Results today, an electronic copy of the Annual Report and Accounts for the year ended 31 December 2016 is now available on the Company's website, www.realmtx.com.
Enquiries:
Hot Features
Premium
+44 (0) 20 3727
Realm Therapeutics plc 1000
Alex Martin, Chief Executive
Officer
Marella Thorell, Chief Financial
Officer and Chief Operating
Officer
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser +44 (0) 20 7496
& Broker) 3000
Aubrey Powell / Lauren Kettle
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSLLFESVSIVFID
(END) Dow Jones Newswires
March 23, 2017 10:57 ET (14:57 GMT)
1 Year Realm Thera. Chart |
1 Month Realm Thera. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
